Align Technology Inc

Company facts

Industry

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Headquarters

Tempe, Arizona

Most recent report

8-K, filed Aug 31, 2026

Incorporated

Delaware

Filings on record

1,001+ filings

On EDGAR

CIK 1097149

Fiscal year ends

December

Filer status

Large accelerated filer

What to read: Jun 2026 10-Q

SECSift found 3 of 13 sections worth reading, with 7 positive, 10 notable, and 5 negative flags.

• Financial Statements (Item 1)

  Comprehensive financials with legal and tax charges driving results.
  Notable

  • Straumann trial: Align won antitrust claims, but four patents found invalid for lack of enablement.
  • April 2025 buyback program has $733.3M remaining after $66.7M repurchased in Q2 2026.
  Negative

  • One borrower represents 72% of $80.4M in convertible notes held by Align.
  • UK VAT liability of $37.5M accrued after Upper Tribunal ruled aligners not exempt, appeal pending.

• Management's Discussion (Item 2)

  UK VAT liability, segment decline, and legal costs are real risks. Results show growth but also concerns.
  Positive

  • Total revenues up 4.3% to $1,056M in Q2 2026 vs Q2 2025.
  • Clear Aligner revenues up 8.2% to $871M in Q2 2026.
  • Clear Aligner case volume up 7.4% year-over-year in Q2 2026.
  • Cash from operations $193M in Q2 2026; $344M for H1, up from $181M.
  • Doctor submitters up 3.4% to 89.2k in Q2 2026 from 86.3k.
  • Utilization rate improved to 7.8 cases per doctor from 7.5 in Q2 2025.
  • Clear aligner revenue per case rose 0.8% to $1,260 in Q2 2026.
  Notable

  • New $200M manufacturing facility in Hyderabad, India announced in Q2 2026.
  • Headcount fell 4.9% to 20,435 due to completed 2025 restructuring ($40.2M charges).
  • Repurchased $98M in H1 2026, $733M left under $1B authorization. Expect to buy $200M over six months starting May 1.
  Negative

  • Systems and Services revenue fell 10.8% to $185M in Q2 2026.
  • Operating margin dropped to 14.6% from 16.1% in Q2 2025, hurt by legal costs.

• Risk Factors (Item 1A)

  Many new company-specific risks: EU antitrust probe, tariff overhaul, QMSR, AI threats.
  Notable

  • Section 301 duties on top 60 trade partners effective July 24, 2026, replacing expired Section 122 surcharges. Indefinite duration.
  • Company now flags AI-powered attacks (deepfakes, generative AI) as increasing cyber threat frequency and sophistication.
  • New FDA Quality Management System Regulation effective February 2, 2026, incorporating ISO 13485:2016.
  • EU AI Act amendments defer high-risk obligations to December 2027/August 2028; company must track compliance.
  • Align states it is currently subject to shareholder activism, which could distract management and cause stock volatility.
  Negative

  • EU formally investigating Align for abuse of dominance in EEA, announced June 29, 2026. Could require business practice changes.

What changed: Jun 2026 vs. Mar 2026

About 8% of ALGN's Jun 2026 10-Q is new information. 45 paragraphs were added, 196 changed, and 35 removed. Below are the most important lines SECSift identified.

• Item 2 75
• Item 1 72
• Item 1A 38
• Item 3 5
• Item 4 2
• Item 6 2
• Item 5 1